bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition Read more about bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million Read more about bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
bluebird bio to Host Third Quarter 2023 Financial Results Conference Call Read more about bluebird bio to Host Third Quarter 2023 Financial Results Conference Call
bluebird bio 3rd Quarter 2023 Results Call Read more about bluebird bio 3rd Quarter 2023 Results Call
Morgan Stanley 21st Annual Global Healthcare Conference Read more about Morgan Stanley 21st Annual Global Healthcare Conference
bluebird bio Announces September Investor Events Read more about bluebird bio Announces September Investor Events
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease Read more about bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease